Biagio Ricciuti, MD, Talks About Prolonged Response to Pembrolizumab Monotherapy in PD-L1–High NSCLC


Biagio Ricciuti, MD, spoke about the 3-year follow-up and prolonged survival benefit in patients with non–small cell lung cancer who had very high PD-L1 expression of 90% or more.

Biagio Ricciuti, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology Annual Meeting, about patients with non–small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 90% or more who had a prolonged response compared with those who had TPS of 50% to 89%.

At the median follow-up of 42.6 months, the median progression-free survival (PFS) in the entire cohort was 5.1 months and the median overall survival (OS) was 19.0 months. Median PFS in expression groups of 90% or more vs 50% to 89% was 6.0 months and 4.5 months, respectively (HR, 0.67; P <.001) and median OS was 30.2 months vs 16.9 months (HR, 0.66; P <.01).


At the 3-year follow-up analysis of the retrospective multicenter study of patients with PD-L1 expression 90% or greater, [patients had] a response rate of 47% which was significantly higher compared with the 32% response rate we observed in the patient cohort with expression of 50% to 80%. This difference in response rate at 3 years translated to a significantly longer median PFS and OS. The median OS was almost 30 months among patients with TPS expression 90% or greater as opposed to 17 months in patients with PD-L1 expression of 50%. The outcomes nearly doubled in this patient population. This suggests a benefit in patients with high PD-L1 expression when compared with chemotherapy. The clinical trial [results were] likely driven by the subset of patients with very high PD-L1 expression. This also suggests that PD-L1 expression acts as a more continuous variable.


Ricciuti B, Elkrief A, Alessi J, et al. Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab. J Clin Oncol. 2022;40(suppl 16):9043. doi: 10.1200/JCO.2022.40.16_suppl.9043

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Expert on NSCLC
Related Content